Precigen

Precigen

Precigen

Add article description

Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Quick Facts Traded as, Industry ...

Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.[2][3] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.[4]

History

In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million.[5] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.[6][7] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.[8][9] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.[7]

See also

References

  1. [1]
    "Precigen Revenue 2012-2021 | PGEN".
  2. [2]
    "Intrexon Corporation: Private Company Information". Bloomberg. Retrieved 2017-06-26.
  3. [3]
    "Intrexon Corp (XON) Company Profile". Reuters.com. Retrieved 2017-06-26.[dead link]
  4. [4]
    "FAQ | Intrexon". Intrexon InvestorRoom. Retrieved 2018-03-28.
  5. [5]
    Nickel, Rod (15 September 2015). "Market turbulence or not, North American investors plow into farm tech". Reuters. Retrieved 9 October 2015.
  6. [6]
    "PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS". FDA. Retrieved 6 April 2020.
  7. [7]
    Gilgore, Sara (6 January 2020). "Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug". American City Business Journals. Retrieved 6 April 2020.
  8. [8]
    "INTREXON CORPORATION IS NOW PRECIGEN, INC". Precigen. Retrieved 6 April 2020.
  9. [9]
    Helmstetter, Michael (30 March 2020). "The Promise And Fear Of Gene Editing". Forbes. Retrieved 6 April 2020.

Official website
Share this article:

This article uses material from the Wikipedia article Precigen, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.